keyword
MENU ▼
Read by QxMD icon Read
search

Antiplatelets

keyword
https://www.readbyqxmd.com/read/30006334/can-we-improve-long-term-outcomes-postbifurcation-stenting-by-prolonged-dual-antiplatelet-therapy
#1
EDITORIAL
John D Horowitz, Peter R Sage
No abstract text is available yet for this article.
July 2018: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/30006330/benefit-of-prolonged-dual-antiplatelet-therapy-after-implantation-of-drug-eluting-stent-for-coronary-bifurcation-lesions-results-from-the-coronary-bifurcation-stenting-registry-ii
#2
Woo Jin Jang, Sung Gyun Ahn, Young Bin Song, Seung-Hyuk Choi, Woo Jung Chun, Ju Hyeon Oh, Sung Woo Cho, Bum Sung Kim, Jung Han Yoon, Bon-Kwon Koo, Cheol Woong Yu, Yang Soo Jang, Seung-Jea Tahk, Hyo-Soo Kim, Hyeon-Cheol Gwon, Sung Yun Lee, Joo-Yong Hahn
BACKGROUND: Whether prolonged dual antiplatelet therapy (DAPT) improves clinical outcomes after percutaneous coronary intervention for coronary bifurcation lesion is uncertain. METHODS AND RESULTS: We evaluated 2082 patients who were treated with drug-eluting stent for bifurcation lesions and were event free (no death, myocardial infarction [MI], cerebrovascular accident, stent thrombosis, or any revascularization) at 12 months after the index procedure. Patients were divided into 2 groups: DAPT ≥12-month group (n=1776) and DAPT <12-month group (n=306)...
July 2018: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/30006115/st-elevation-acute-myocardial-infarction-in-australia-temporal-trends-in-patient-management-and-outcomes-1999-2016
#3
Bernadette Aliprandi-Costa, Lucy Morgan, Lan-Chi Snell, Mario D Souza, Leonard Kritharides, John French, David Brieger, Isuru Ranasinghe
BACKGROUND: Increased access to reperfusion for ST elevation myocardial infarction (STEMI) has contributed to reduced mortality internationally. We describe temporal trends in pre-hospital care, in-hospital management and outcomes of the STEMI population in Australia. METHODS: Temporal trends with multiple regression analysis on the management and outcomes of STEMI patients enrolled across 46 Australian hospitals in the Australian cohort of the Global Registry of Acute Coronary Events (GRACE) and the Cooperative National Registry of Acute Coronary Care Guideline Adherence and Clinical Events (CONCORDANCE) between February 1999 and August 2016...
June 11, 2018: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/30004572/antiplatelet-and-anticoagulant-agents-for-primary-prevention-of-thrombosis-in-individuals-with-antiphospholipid-antibodies
#4
REVIEW
Malgorzata M Bala, Elżbieta Paszek, Wiktoria Lesniak, Dorota Wloch-Kopec, Katarzyna Jasinska, Anetta Undas
BACKGROUND: Antiphospholipid syndrome (APS) is an autoimmune disease characterised by the presence of antiphospholipid (aPL) antibodies that have prothrombotic activity. Antiphospholipid antibodies are associated with an increased risk of pregnancy complications (recurrent miscarriage, premature birth, intrauterine growth retardation) and thrombotic events (both arterial and venous). The most common thrombotic events include brain ischaemia (stroke or transient ischaemic attack) and deep vein thrombosis...
July 13, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/30004271/evaluation-of-potential-drug-drug-interactions-with-direct-oral-anticoagulants-in-a-large-urban-hospital
#5
Yoonsun Mo, Ayse Karakas-Torgut, Antony Q Pham
OBJECTIVE: The aim of this study is to assess patterns of potential drug-drug interactions (DDIs) with direct oral anticoagulants (DOACs) in an inpatient hospital setting. METHODS: A retrospective chart review was conducted at the Brookdale University Hospital and Medical Center (BUHMC) from January 2014 to November 2016. All adult patients admitted to the BUHMC who were treated with a DOAC for at least 3 days were screened. Among them, those who received selected interacting drugs at any time during the course of DOAC therapy were included in this study...
January 1, 2018: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/30003466/assessment-of-the-risk-of-rhabdomyolysis-and-myopathy-during-concomitant-treatment-with-ticagrelor-and-statins
#6
REVIEW
Dorota Danielak, Marta Karaźniewicz-Łada, Franciszek Główka
The introduction of ticagrelor, one of the first directly-acting oral antiplatelet drugs, provided new possibilities in the prevention of thrombotic events in patients with acute coronary syndromes (ACS). Current guidelines recommend ticagrelor in dual antiplatelet therapy with aspirin over clopidogrel for prevention of stent thrombosis in patients with ACS. Moreover, in the management of ACS, lipid-lowering treatment with high-intensity statin therapy is advised for secondary prevention of cardiovascular events over the long term...
July 12, 2018: Drugs
https://www.readbyqxmd.com/read/30002694/standardised-tomato-extract-as-an-alternative-to-acetylsalicylic-acid-in-patients-with-primary-hypertension-and-high-cardiovascular-risk-a-randomised-controlled-trial
#7
Beata Krasinska, Angelika Osińska, Maciej Osinski, Aleksandra Krasinska, Piotr Rzymski, Andrzej Tykarski, Zbigniew Krasiński
Introduction: Cardiovascular (CV) diseases remain a leading global cause of death. It has been proven that the use of acetylsalicylic acid (ASA) in secondary prevention reduces the CV risk, while the benefits of ASA in primary prevention have recently been debated. The aim of the study was to compare the antiplatelet effect of standardised tomato extract (STE) and ASA in hypertensive patients with high CV risk. Material and methods: The study involved high-risk patients with arterial hypertension (AH) randomly assigned to one of two groups: group 1 included 33 patients receiving ASA and group 2 included 32 patients receiving STE...
June 2018: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/30001456/multiple-electrode-aggregometry-as-a-method-for-platelet-function-assessment-according-to-the-european-guidelines
#8
Jan Pluta, Barbara Nicińska, Janusz Trzebicki
Platelets play an essential role in haemostasis. Assessment of their function is vital for anaesthesiologists evaluating haemostatic potential, especially during emergency operations. The monitoring of platelets function had been implemented into the European recommendations for management of perioperative and posttraumatic bleeding. One of the diagnostic methods described in the recommendations is multiple electrode aggregometry. As antiplatelet therapy becomes more widely used in modern medicine, this method, in contrast to standard laboratory tests, can significantly help to identify patients with drug-induced thrombocytopaty...
July 12, 2018: Anaesthesiology Intensive Therapy
https://www.readbyqxmd.com/read/29998574/cyp3a4-22-impairs-the-elimination-of-ticagrelor-but-has-no-significant-effect-on-the-bioactivation-of-clopidogrel-or-prasugrel
#9
Mikko T Holmberg, Aleksi Tornio, Maria Paile-Hyvärinen, E Katriina Tarkiainen, Mikko Neuvonen, Pertti J Neuvonen, Janne T Backman, Mikko Niemi
CYP3A enzymes participate in the elimination of ticagrelor and the bioactivation of clopidogrel and prasugrel. We studied the effects of functional CYP3A genetic variants (CYP3A4*22; rs35599367 and CYP3A5*3; rs776746) on the pharmacokinetics and pharmacodynamics of ticagrelor, clopidogrel, and prasugrel. Six healthy volunteers with the CYP3A4*1/*22 and CYP3A5*3/*3 genotype (CYP3A4*22 carriers), eight with the CYP3A4*1/*1 and CYP3A5*1/*3 genotype (CYP3A5 expressors), and 11 to 13 with the CYP3A4*1/*1 and CYP3A5*3/*3 genotypes (controls) ingested single doses of ticagrelor, clopidogrel, and prasugrel on separate occasions...
July 11, 2018: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29997196/diagnosing-cerebral-ischemia-with-door-to-thrombolysis-times-below-20-minutes
#10
Saana Pihlasviita, Olli S Mattila, Juhani Ritvonen, Gerli Sibolt, Sami Curtze, Daniel Strbian, Heini Harve, Mikko Pystynen, Markku Kuisma, Turgut Tatlisumak, Perttu J Lindsberg
OBJECTIVES: To clarify diagnostic accuracy and consequences of misdiagnosis in the admission evaluation of stroke-code patients in a neurologic emergency department with less than 20-minute door-to-thrombolysis times. METHODS: Accuracy of admission diagnostics was studied in an observational cohort of 1,015 stroke-code patients arriving by ambulance as candidates for recanalization therapy between May 2013 and November 2015. Immediate admission evaluation was performed by a stroke neurologist or a neurology resident with dedicated stroke training, primarily utilizing CT-based imaging...
July 11, 2018: Neurology
https://www.readbyqxmd.com/read/29995658/ibrutinib-related-bleeding-pathogenesis-clinical-implications-and-management
#11
Carlos Aguilar
: Ibrutinib is the first drug of a new family of Bruton's tyrosine kinases (Btk)-inhibiting agents, which have proved to be useful for the treatment of several B-cell lymphoid malignancies. This drug is associated to an increased bleeding risk from initial clinical trials especially in association with warfarin. Although Btk plays an important role in platelet signalling, increased bleeding tendency in patients on ibrutinib is more complex than Btk inhibition alone and is because of several antiplatelet mechanisms, namely inhibition of Btk and Tec kinases, which play a key role in platelet activation downstream of the collagen GPVI and Glycoprotein Ib...
July 10, 2018: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/29995228/a-novel-bridging-strategy-for-patients-undergoing-emergent-non-cardiac-surgery-with-a-recent-coronary-stent
#12
Cierra Bruck, Omar Jafar, Jayne Prats, Deepak Bhatt, Zubair Jafar
INTRODUCTION: Not infrequently, patients undergoing dual antiplatelet therapy for a recent cardiac stent develop a need for a non-cardiac surgery. Most of these surgeries can be delayed while the antiplatelet treatment is stopped and normal platelet function returns in order to avoid potential surgical complications and excessive bleeding. However, there are a number of patients who require urgent surgery where the procedure cannot be postponed. To date, no agents have been proven to bridge the patient off dual-antiplatelet therapy...
July 11, 2018: Cardiology and Therapy
https://www.readbyqxmd.com/read/29995218/lmu-munich-platelet-inhibition-novel-aspects-on-platelet-inhibition-and-function
#13
REVIEW
Lisa Gross, Dirk Sibbing, Christian Schulz, Florian Gärtner, Joachim Pircher, Steffen Massberg, Tobias Petzold
A core research area in the Department of Cardiology at Ludwig-Maximilians-University (LMU) Munich focuses on antiplatelet therapy, its translational aspects, and its underlying mechanism with respect to platelet physiology. We are conducting a broad range of investigator-initiated clinical trials (phase II-IV) and preclinical studies on the topic of antithrombotic therapy for percutaneous coronary intervention patients, platelet activation, and reactivity as well as on novel inhibitors of platelet adhesion...
July 11, 2018: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/29995131/anticoagulants-and-antiplatelet-drugs-during-cataract-surgery
#14
Newton Kara-Junior, Camila Ribeiro Koch, Marcony Rodrigues de Santhiago, Luciana Fornari, Bruno Caramelli
Patients undergoing cataract surgery are generally elderly, and many take drugs with systemic effects. The surgeon must be aware of the risks of continuing or discontinuing such medications perioperatively. Antiplatelet drugs and anticoagulants, prescribed to reduce the incidence of thromboembolic events, are often used in this population. This paper aims to review the perioperative use of antiplatelet and anticoagulant drugs in the setting of cataract surgery. Topical or intracameral anesthesia is preferred over anesthesia injected with needles...
July 2018: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/29991646/defining-exposure-in-observational-studies-comparing-outcomes-of-treatment-discontinuation
#15
Alexis A Krumme, Robert J Glynn, Sebastian Schneeweiss, Niteesh K Choudhry, Angela Y Tong, Joshua J Gagne
BACKGROUND: Continuation of antiplatelet therapy beyond 12 months after a drug-eluting stent procedure reduced the risk of a major adverse cardiovascular and cerebrovascular event (MACCE) in the DAPT trial (Dual Antiplatelet Therapy). Observational studies have evaluated outcomes related to different durations of therapy but are susceptible to bias. METHODS AND RESULTS: Using deidentified claims from commercially insured and Medicare populations in the United States, we compared how increasingly stringent definitions of exposure affect associations between antiplatelet continuation versus discontinuation and MACCE, myocardial infarction, and intracerebral hemorrhage or gastrointestinal bleeding in patients meeting DAPT trial inclusion criteria between 2004 and 2013...
July 2018: Circulation. Cardiovascular Quality and Outcomes
https://www.readbyqxmd.com/read/29991269/does-ticagrelor-improve-endothelial-function
#16
Athanasios Moulias, Ioanna Xanthopoulou, Dimitrios Alexopoulos
Ticagrelor is a P2Y12 receptor antagonist with proven clinical benefit in patients with acute coronary syndrome. Apart from its principal antiplatelet action, pleiotropic effects have been implicated in the clinical profile of ticagrelor, including a potentially beneficial impact on endothelial function. In light of the common presence and prognostic value of endothelial dysfunction in patients with coronary artery disease, several clinical studies have investigated the postulated effect of ticagrelor on endothelial function, yielding conflicting results...
January 1, 2018: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29990874/therapeutic-effects-of-jlx001-on-cerebral-ischemia-through-inhibiting-platelet-activation-and-thrombus-formation-in-rats
#17
Yun-Yi Yan, Lu-Yao Ao, Lin Zhou, Cheng-Yuan Li, Wei-Rong Fang, Wei-Yang Shen, Bing-Wen Liang, Xiong Zhu, Yun-Man Li
(3β,5α,16α,20S)-4,4,14-trimethyl-3,20-bis(methylamino)-9,19-cyclopregnan-16-ol-dihydrochloride (JLX001), a derivative of cyclovirobuxine D (CVB-D), is a novel compound from synthesis. This study aims to confirm the therapeutic effect of JLX001 on cerebral ischemia and researchits antiplatelet and antithrombosis activities via thromboxane (TXA2 )/phospholipase C-β-3(PLCβ3)/protein kinase C (PKC) pathway suppression. The therapeutic effects of JLX001 was evaluated by infarct sizes, brain edema and neurological scores in Sprague-Dawley (SD) rats with middle cerebral artery occlusion (MCAO)...
July 7, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29990542/pleiotropic-effects-of-antiplatelet-treatment-in-patients-with-coronary-artery-disease
#18
EDITORIAL
Gerasimos Siasos, Konstantinos Mourouzis, Dimitrios Tousoulis
No abstract text is available yet for this article.
July 7, 2018: Hellenic Journal of Cardiology: HJC, Hellēnikē Kardiologikē Epitheōrēsē
https://www.readbyqxmd.com/read/29989599/-dual-antiplatelet-therapy-in-elderly-patients-with-acute-coronary-syndrome-does-age-make-the-difference
#19
Giuseppe Tarantini, Plinio Cirillo, Stefano De Servi, Guido Parodi, Davide Capodanno, Gianpiero D'Amico, Alessandro Boccanelli, Marco Cattaneo, Leonardo Bolognese, Claudio Cavallini, Giuseppe Musumeci, Niccolò Marchionni
The appropriate use of dual antiplatelet therapy (DAPT) in elderly patients with acute coronary syndrome (ACS) remains a highly debated subject. In fact, achieving the correct balance between the reduction of ischemic risk and the increase in hemorrhagic events is more difficult in this population than in younger subjects, especially in the case of very potent drug therapy. As a consequence of this, despite guideline recommendations, antiplatelet therapy is currently underutilized in elderly patients with ACS...
July 2018: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/29987818/badimon-perfusion-chamber-an-ex-vivo-model-of-thrombosis
#20
M Urooj Zafar, Carlos G Santos-Gallego, Lina Badimon, Juan J Badimon
The Badimon perfusion chamber is an ex vivo model of thrombosis that assesses the thrombogenicity of blood in humans and large animals. It works with native blood thereby excluding any interfering effects of anticoagulants unavoidable with the majority of platelet function testing methodologies. Each variable of the Virchow's triad (blood, blood flow, and endothelial wall) that modulates blood-vessel wall interaction and thrombus formation is incorporated in this perfusion model. These features make this device a valuable tool for the assessment of thrombogenic potential of various diseases and also gauging the efficacy of antithrombotic (anticoagulant and antiplatelet) treatments...
2018: Methods in Molecular Biology
keyword
keyword
508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"